✦ LIBER ✦

Treatment of Hemophilia with Inhibitors: An Advance in Options for Pediatric Patients

✍ Scribed by Joan McCarthy; Prasad Mathew

Book ID: 113706109
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 94 KB
Volume: 37
Category: Article
ISSN: 1527-2966
DOI: 10.1016/j.jen.2010.03.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PSY15 Lifetime Impact of On-Demand Treat

PSY15 Lifetime Impact of On-Demand Treatment Options on Bleeding, Hospitalization, and QOl in Italian Hemophilia Patients With Inhibitors

✍ S.P. Bilir; A.A. Petrilla; K. Trochlil; J. Weatherall; W.C. Lee 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PSY29 Lifetime Impact on Bleeding Episod

PSY29 Lifetime Impact on Bleeding Episodes and Hospitalization of On-Demand Treatment Options in French Hemophilia Patients With Inhibitors

✍ A.A. Petrilla; P. Bilir; K. Trochlil; J. Weatherall; W.C. Lee 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Systematic review of efficacy of rFVIIa

Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors

✍ Chris Knight; Anne Møller Danø; Tessa Kennedy-Martin 📂 Article 📅 2009 🏛 Springer Healthcare Communications 🌐 English ⚖ 441 KB

Advances in treatment of chronic myeloge

Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors

✍ Santos, Fabio P. S.; Ravandi, Farhad 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 296 KB

Soft Tissue Sarcoma: An Update on System

Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease

✍ Schöffski, Patrick; Cornillie, Jasmien; Wozniak, Agnieszka; Li, Haifu; Hompes, D 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 114 KB

Factors affecting choice of hemostatic a

Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody

✍ Paul E. Monahan; Louis M. Aledort 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

## Abstract Achieving adequate hemostasis in patients with hemophilia and high‐titer inhibitor antibodies remains a challenge despite the development of plasma‐derived and recombinant therapies to bypass the inhibitory effect. A group of hemophilia treaters met to examine the factors that influence